135 related articles for article (PubMed ID: 2495717)
21. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
22. In vitro simulation of therapeutic plasmatic fibrinolysis.
Stief TW; Bünder R; Richter A; Maisch B; Renz H; Fareed J
Clin Appl Thromb Hemost; 2003 Jul; 9(3):211-20. PubMed ID: 14507109
[TBL] [Abstract][Full Text] [Related]
23. Inherited disorders of the fibrinolytic pathway.
Jain S; Acharya SS
Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
Wojta J; Binder BR; Huber K; Hoover RL
Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
[TBL] [Abstract][Full Text] [Related]
25. Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Ozdemir O; Emri S; Karakoca Y; Sayinalp N; Akay H; Dündar S; Bariş I
Thromb Res; 1996 Oct; 84(2):121-8. PubMed ID: 8897701
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator and fibrinogen/fibrin degradation products at conization of the uterine cervix.
Larsson G; Astedt B
Acta Obstet Gynecol Scand; 1986; 65(4):331-3. PubMed ID: 3090852
[TBL] [Abstract][Full Text] [Related]
27. DDAVP induces systemic release of urokinase-type plasminogen activator.
Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Braat EA; Levi M; Bos R; Haverkate F; Lassen MR; de Maat MP; Rijken DC
J Lab Clin Med; 1999 Aug; 134(2):161-7. PubMed ID: 10444030
[TBL] [Abstract][Full Text] [Related]
29. Functional assay of plasminogen activator by hydrolysis of 14C-globin.
Finci Z; Nachshon I; Sharoni Y; Mayer M
Exp Hematol; 1986 May; 14(4):293-7. PubMed ID: 2938980
[TBL] [Abstract][Full Text] [Related]
30. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
[TBL] [Abstract][Full Text] [Related]
31. The fibrinolytic system in neoplasia.
Bell WR
Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
[TBL] [Abstract][Full Text] [Related]
32. [Dysfunction of fibrinolysis as a risk factor of thrombosis].
Kołodziejczyk J; Wachowicz B
Pol Merkur Lekarski; 2009 Oct; 27(160):341-5. PubMed ID: 19928667
[TBL] [Abstract][Full Text] [Related]
33. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolytic activity and species of plasminogen activator in human tears.
Hayashi K; Sueishi K
Exp Eye Res; 1988 Feb; 46(2):131-7. PubMed ID: 3127227
[TBL] [Abstract][Full Text] [Related]
35. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
36. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
37. Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases.
Munkvad S; Gram J; Jespersen J
Scand J Rheumatol; 1989; 18(5):277-82. PubMed ID: 2512638
[TBL] [Abstract][Full Text] [Related]
38. Methods for studying fibrinolytic pathway components in human plasma.
Wohl RC; Sinio L; Robbins KC
Thromb Res; 1982 Sep; 27(5):523-35. PubMed ID: 6217585
[TBL] [Abstract][Full Text] [Related]
39. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells.
Uchiba M; Imamura T; Hata H; Tatetsu H; Yonemura Y; Ueda M; Wada Y; Mitsuya H; Ando Y
Amyloid; 2009; 16(2):89-93. PubMed ID: 20536401
[TBL] [Abstract][Full Text] [Related]
40. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
